Please provide your email address to receive an email when new articles are posted on . Through an evolution that has seen several prototypes enter and leave the scene, ultra-small drainage devices ...

A tiny medical device no larger than an eyelash may significantly reduce eye pressure in glaucoma patients and allow some to stop using eye-drop medications, according to year-one clinical trial ...

Three years after Alcon pulled its CyPass Micro-Stent from the market due to safety concerns, the Novartis spinoff has found another glaucoma treatment device to take its place. The Hydrus Microstent ...

The Hydrus Microstent is about the size of an eyelash.--Courtesy of Ivantis Ivantis' eyelash-sized eye stent helped lower intraocular pressure after one year in patients who have undergone cataract ...

Alcon is getting a second shot at competing in the minimally invasive glaucoma surgery (MIGS) market. The Geneva, Switzerland-based company has announced its intention to acquire Ivantis, the ...

A study accepted for publication in the journal Ophthalmology could give Ivantis a competitive advantage against one of the top players in the micro invasive glaucoma surgery space. Dubbed, “COMPARE,” ...

Irvine-based Ivantis Inc., an 11-year-old ophthalmic device maker of eyelash-sized stents used to treat glaucoma, couldn’t pick a better time to bring its first product, Hydrus Microstent, to market ...

CHICAGO -- For the first time in a multicenter randomized trial, minimally invasive glaucoma surgery (MIGS) with an intracanalicular (Schlemm's canal) stent significantly reduced long-term vision loss ...

Other implants, namely the Hydrus Microstent (Ivantis) and the first- and u2028second-generation iStent trabecular micro-bypass (Glaukos) target the Schlemm’s canal, while the third-generation iStent ...

Thomas W. Samuelson, M.D., glaucoma specialist with Minnesota Eye Consultants, served as the HYDRUS I trial's medical monitor Click here for high-resolution version The Hydrus stent is one of several ...